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SUMMARY
The Hedgehog (Hh) pathway plays critical roles in normal development and in tumorigenesis. We generated
Gli-luciferase transgenic mice to evaluate the Smo inhibitor, HhAntag, by whole animal functional imaging.
HhAntag rapidly reduced systemic luciferase activity in 10- to 14-day-old mice following oral dosing. Al-
though pathway activity was restored 2 days after drug removal, brief inhibition caused permanent defects
in bone growth. HhAntag inhibited proliferation and promoted differentiation of chondrocytes, leading to dra-
matic expansion of the hypertrophic zone. After drug removal, osteoblasts invaded the cartilage plate, min-
eralization occurred, and there was premature fusion of the growth plate resulting in permanent disruption of
bone epiphyses.INTRODUCTION
Signal transduction pathways govern cell proliferation and differ-
entiation throughout development. Persistent signaling, as a con-
sequence of mutation or epigenetic modulation of specific path-
way components in cancer cells, promotes unrestrained cell
growth and can result in tumorigenesis. Recent studies support
the notion that targeting aberrantly activated signal transduction
pathways in selected cancers, using small molecule inhibitors,
greatly increases response rates while reducing toxic side ef-
fects (Arora and Scholar, 2005; Savage and Antman, 2002; Sil-
vestri and Rivera, 2005). The hedgehog (Hh) pathway provides
an attractive potential target in many cancers because of its pro-
posed widespread role in maintaining cancer stem cells, either
intrinsically or extrinsically (Dellovade et al., 2006). Hh signaling
is critical for many processes during embryonic and postnatal
development, including proliferation, differentiation, cell fate
specification, left-right asymmetry, and morphogenesis (McMa-
hon et al., 2003). Sporadic and familial mutations in the Hh path-
way genes, patched-1 (PTCH1), suppressor-of-fused (SUFU),
and smoothened (SMO), leading to elevated expression of
downstream target genes including GLI1, have been reported
in basal cell carcinoma (BCC) and the pediatric brain tumor me-
dulloblastoma (MB) (Fogarty et al., 2005; Gorlin, 1995). In addi-
tion, growth of many cancers has been suggested to depend
on continuous Hh signaling even in the absence of activating mu-
tations in the pathway (Evangelista et al., 2006).
Potential therapeutic agents specific for the Hh pathway were
identified initially as plant alkaloid teratogens that cause holopro-
sencephaly when ingested by pregnant sheep during a critical
period in the first trimester (Binns et al., 1963; Binns et al.,
1965; Keeler, 1972). Subsequently, they were shown to function
by binding to SMO to block downstream signaling, thus inhibit-
ing proliferation (Chen et al., 2002; Cooper et al., 1998). Several
structurally unrelated compounds have now been isolated that
function in the same manner (Gabay et al., 2003; Williams
SIGNIFICANCE
Hh pathway inhibitors are currently being developed as potential therapies for several cancers, including pediatric medul-
loblastoma. Functional imaging studies in youngmice demonstrated that blocking the pathway for as little as 2 days caused
permanent defects in bone growth. The aberrant structures formed could not be removed by bone remodeling, so the de-
fects were permanent. These results demonstrate a requirement for uninterrupted Hh pathway signaling during postnatal
bone development. In addition, our findings raise concerns about the use of Hh pathway inhibitors in pediatric patients,
and they point to a broader issue regarding the use of signal transduction inhibitors in children.Cancer Cell 13, 249–260, March 2008 ª2008 Elsevier Inc. 249
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tion as potential anticancer therapies, particularly in tumors car-
rying PTCH1 mutations such as BCC and MB (Athar et al., 2004;
Berman et al., 2002; Romer et al., 2004; Sanchez and Ruiz i Al-
taba, 2005). In mice, heterozygous mutation of Patched-1
(Ptc1) results in a 20% incidence of MB, and this is accelerated
to 100% on a p53 null background (Goodrich et al., 1997; Kimura
et al., 2005; Wetmore et al., 2000; Wetmore et al., 2001). Previ-
ously, we conducted proof-of-principle studies in these mice us-
ing an inhibitor of SMO (HhAntag) (Romer et al., 2004). Treatment
of mice with HhAntag eradicated spontaneous MB without caus-
ing any serious side effects. The findings were confirmed in
transplantation models, using tumors from a variety of mouse
MBs, including some with no known mutations in the Hh pathway
(Sasai et al., 2006, 2007). These results encouraged us to con-
sider the use of Smo inhibitors for treatment of the subset of
childhood MB in which the Shh pathway is activated (Thompson
et al., 2006).
As a next step in this process, we developed a functional im-
aging system for the analysis of Hh pathway antagonists
in vivo. Here, we show that GliLuc mice can be used to monitor
the response of the Shh pathway to agonists and antagonists by
intravital imaging. Treatment of young mice with as little as two
doses of 100 mg/kg HhAntag within a 24 hr period transiently in-
hibited Hh pathway activity, which was restored 48 hr after drug
removal. However, to our surprise, brief exposure to the Smo in-
hibitor resulted in permanent defects in bone development.
HhAntag blocked proliferation of chondrocytes promoting differ-
entiation and expansion of the hypertrophic zone. Shortly after
drug removal, there was a dramatic increase in mineralization
leading to premature fusion of the growth plate and inappropri-
ate synthesis of trabecular bone. The disruption of the bone
epiphyses persisted in adults resulting in shortening of the bones
and aberrant joint structures. Even transient exposure to HhAn-
tag resulted in a dramatic loss of proliferating chondrocytes, de-
pletion of the progenitor pool, and permanent disruption of the
growth plate. These findings raise serious concerns about the
use of Hh pathway antagonists in children and they pose
a broader question about the potential developmental toxicities
of signal transduction inhibitors. Since many signaling pathways
fulfill specific roles during development, it would be prudent to
investigate the effects of molecular targeted therapies in devel-
oping animal models prior to their use in pediatric patients.
RESULTS
Generation of GliLuc Mice and Functional Imaging
of Hh Pathway Activity
Hh activity can be readily monitored by optical imaging in cells
transfected with a plasmid containing eight Gli binding sites
fused to the d-crystallin basal promoter and the firefly luciferase
gene (Kamachi and Kondoh, 1993; Sasaki et al., 1997). We used
this same construct to generate six independent lines of trans-
genic mice by microinjection. Primary granule cell cultures
were prepared from litters obtained from each strain and tested
for their ability to respond to Shh. Five lines did not show any
change in luciferase activity in response to Shh, perhaps be-
cause transgene expression was suppressed by sequences sur-
rounding the site of integration. However, one line exhibited a250 Cancer Cell 13, 249–260, March 2008 ª2008 Elsevier Inc.robust Shh-induced increase in luciferase activity and this was
selected to generate a cohort of GliLuc mice for future studies.
The Hh pathway is very active during embryogenesis and
postnatal central nervous system development (McMahon
et al., 2003). As expected, GliLuc transgenic embryos (visualized
through the skin of the dam) exhibited a robust luciferase signal
within 15 min of inoculating the dam with 150 mg/kg D-Luciferin
by intraperitoneal (IP) injection (Figure 1A). As gestation pro-
gressed, GliLuc transgenic embryos showed increased lucifer-
ase activity (Figure 1A). Embryos isolated at E17.5 were positive,
with a particularly strong signal emanating from the developing
brain (Figure 1B).
To determine the ability of the transgene to respond to Shh
stimulation, mouse embryo fibroblast (MEF) cultures were pre-
pared and treated with Shh for 48 hr before measuring the level
of luciferase activity. As shown in Figure 1C, as little as 50 ng/ml
Shh caused a dramatic increase in luciferase activity when mea-
sured by bioluminescence imaging or chemiluminescence bio-
chemical assays. The maximal response was obtained with
100 ng/ml Shh, which is identical to the concentration required
to promote maximal proliferation of primary granule cells in cul-
ture (data not shown). Since there was no basal activity in un-
treated fibroblasts, it is not meaningful to calculate a fold re-
sponse. The ability of HhAntag to block Hh signaling was
determined using a dose of 100 ng/ml Shh. The half-maximal re-
sponse (EC50) was observed at a concentration of 0.15 mM
HhAntag. This is consistent with previous reports using trans-
fected cell lines (Romer et al., 2004).
The ability of HhAntag to suppress Hh pathway activity in em-
bryos was investigated by treating pregnant dams with HhAntag
at 100 mg/kg twice daily by oral gavage at both E13.5 and E14.5
(Figure 1A). The signals observed from treated embryos were di-
minished compared to those from untreated embryos. At the end
of the study we examined the embryos and found evidence of
shortened limbs as a consequence of exposure to HhAntag
(data not shown).
To examine Hh pathway activity during postnatal develop-
ment, we quantified the GliLuc signal in pups from postnatal
days 1, 7, and 14, as well as in young adults at 5 and 11 weeks
of age (Figure 1D). Hh pathway activity was very high shortly after
birth, and then it progressively declined throughout the course of
postnatal development (Figure 1D). Little or no GliLuc signal was
detected in 11-week-old mice. Although the imaging approach
mostly detects superficial signals in skin tissue, the skin still ex-
hibited the highest level of pathway activity when compared with
other dissected mouse tissues including brain, liver, lung, kid-
ney, heart, and spleen (data not shown). During early mouse
postnatal development, epidermal and dermal progenitors ac-
tively proliferate to form hair and nonhair epithelium as well as
stratified epidermis (Fuchs, 2007), and proliferation of these pro-
genitors cells is under tight control by the Hh pathway (Callahan
and Oro, 2001). However, in contrast, in the adult skin epithelium,
the expression levels of Shh, Gli1, and Gli2 are very low.
Hh Pathway Activity Is Temporarily Inhibited in Young
Mice Treated with HhAntag
To evaluate the ability of HhAntag to inhibit Hh pathway activity
in vivo, we imaged luciferase activity in young GliLuc mice fol-
lowing treatment with HhAntag (Figure 2). Previously, we found
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or HhAntag were given orally, twice daily, at 50 mg/kg. Cyclo-
pamine reduced the level of GliLuc activity in treated mice but
it was less potent than HhAntag, even after a total of eight doses
(see Figures S1A and S1B available online). These in vivo data
are comparable with previous studies carried out in cell culture
experiments (Romer et al., 2004; Williams et al., 2003)
(Figure S1). After drug removal, Hh pathway activity rapidly re-
covered, as observed previously with HhAntag treatment
(Figure S1C and Figure 2G). Longer treatment periods were not
possible due to acute weight loss and dehydration in cyclo-
pamine-treated mice (Figure S1D). Thus, because of the dose-
limiting toxicity, cyclopamine cannot be used to completely sup-
press systemic GliLuc activity in vivo.
Transient Exposure of Young Mice to HhAntag
Causes Permanent Bone Defects
In our previous studies in adult mice, we did not observe any
weight loss or growth retardation following twice daily treatment
with 100 mg/kg HhAntag for 2 weeks. Therefore, we were sur-
prised to note that young mice, from P10 to P14, treated with
HhAntag did not thrive. In fact, they lost weight during the period
of drug treatment (Figure 3A, day 10 to 14). However, the effect ofthat treatment of Ptc1+/p53/ mice with HhAntag, given twice
daily by oral gavage at 100 mg/kg, downregulates Gli1 expres-
sion in tumor cells within 4 days and eradicates tumor volume af-
ter 2 weeks (Romer et al., 2004; Sasai et al., 2006). Lowering the
dose of HhAntag to 20 mg/kg caused partial suppression of Gli1
expression and incomplete regression of MB. Here, GliLuc mice
were treated at postnatal day 10 (P10), with a range of HhAntag
doses (10, 25, 50, and 100 mg/kg), twice daily by oral gavage,
and the level of luciferase activity suppression after 1 and 2
days of treatment was quantified (Figure 2A). The results indi-
cated that HhAntag partially blocked Hh pathway activity in
skin at 10 mg/kg and completely suppressed activity at 25, 50,
and 100 mg/kg HhAntag (Figure 2B). A strong GliLuc signal
was observed in the head of treated mice, perhaps because
the thinner skull in young mice is less effective at blocking the
luciferase signal from the brain (Figure 2).
The time course of inhibition was monitored in GliLuc mice
treated with 100 mg/kg HhAntag twice daily for a total of eight
doses from P10 to P14. After two doses, the level of Hh pathway
activity was significantly decreased (Figures 2C–2E). The reduc-
tion in activity was sustained throughout the entire treatment pe-
riod (Figure 2F). Two doses of HhAntag were sufficient for max-
imum suppression of Hh pathway activity as the GliLuc signalCFigure 1. Functional Imaging of Shh Pathway Activity in Gli-
Luc Transgenic Mice
(A) Images of wild-type female mice previously mated with a trans-
genic GliLuc male mouse after injection of 150 mg/kg D-Luciferin.
Control and pregnant (Vehicle- and HhAntag-treated) mice were
placed on their backs and imaged using a Xenogen IVIS200 Bioimag-
ing system. Pregnant mice were imaged at 12.5 days postcoitum (dpc)
(pretreatment), at 13.5 dpc (two-dose treatment), and 14.5 dpc (four-
dose treatment). Mice were imaged untreated (control), 5 hr after treat-
ment with Vehicle, or with 100 mg/kg HhAntag.
(B) Images of wild-type and GliLuc transgenic embryos at 17.5 dpc.
Embryos were removed after intraperitoneal inoculation of the dam
with D-Luciferin.
(C) Cell-based bioluminescence images (upper) and luminescence as-
says (lower) of MEFs from GliLuc mice at E13.5 treated with increasing
doses of Shh. RLA, relative luciferase activity. Data are the mean ± SD
(triplicate).
(D) Downregulation of Hh pathway activity during postnatal develop-
ment. Grayscale photograph and bioluminescence images of GliLuc
mice at P1, P7, and P14 as well as 5 and 11 weeks of age. Graph
shows the Gliluc signal intensity (photons per second) per body weight
(gram). Data indicate mean ± SD (n = 3).
was not further reduced by additional treatment. Pathway
activity recovered within 2 days of drug removal
(Figure 2G). These data demonstrate that suppression
of Hh pathway activity by HhAntag in young mice is tran-
sient and rapidly reversible.
Previous studies indicated that cyclopamine, a naturally
occurring plant alkaloid, caused regression of MB and
other tumors in several mouse transplantation models
(Berman et al., 2002, 2003; Karhadkar et al., 2004; San-
chez et al., 2005). In vitro, cyclopamine is approximately
10-fold less active than HhAntag at suppressing Hh activ-
ity (Romer et al., 2004). We compared the effects of cy-
clopamine and HhAntag on Hh pathway activity in young
GliLuc mice. We were precluded from using cyclopamineancer Cell 13, 249–260, March 2008 ª2008 Elsevier Inc. 251
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HhAntag in Young Mice
(A) Dose-dependent suppression of GliLuc activity by HhAntag.
Five GliLuc transgenic males at P10 were treated with HhAntag
at the indicated drug concentrations. Bioluminescence images
were captured at P11 (1 day after HhAntag treatment) and at
P12 (2 days after treatment).
(B) Graph showing quantitation of Hh pathway activity at each
dose. Signals were measured on three different images obtained
from each mouse after D-Luciferin had equilibrated. Values shown
are mean ± SD. Activity in the mouse treated with 0 mg/kg (blue
diamonds) was designated as 100%. Pink squares, HhAntag 10
mg/kg; yellow triangles, 25 mg/kg; light blue crosses, 50 mg/kg;
purple stars, 100 mg/kg.
(C–G) Time-course of Hh pathway suppression and recovery.
Grayscale photographs of P10 mice (given Vehicle or 100 mg/kg
HhAntag) were compared with images and graphs of biolumines-
cence signals in the same two mice at P10 (before treatment), P11
after two doses of HhAntag, P14 after eight doses, and P16 2 days
after the eight-dose treatment period. Values shown are mean ±
SD. V, Vehicle; H, HhAntag.
examination and necropsy of 12-week-old treated
mice. These observations are consistent with the criti-
cal role the hedgehog pathway is known to play in bone
development (Ehlen et al., 2006). Deletion of Indian Hh
(Ihh) causes embryonic lethality in mice (St-Jacques
et al., 1999), conditional ablation results in a phenotype
similar to that reported here (Maeda et al., 2007), and
hypomorphic mutations of IHH in humans cause acro-
capitofemoral dysplasia (Hellemans et al., 2003).
We investigated the effects of HhAntag treatment
duration on bone development in normal mice. Mice
were treated with 100 mg/kg HhAntag at P10 twice
daily for 1–4 days, and the effects on bone develop-HhAntag was less severe than that observed with cyclopamine,
and we did not see any evidence of dehydration. Although the
HhAntag-treated mice regained weight after cessation of treat-
ment, they never caught up with their littermates (Figure 3A),
and they remained noticeably smaller than control mice even
long after the brief 4 day treatment period (Figure S2A). This sug-
gested that short-term treatment with HhAntag permanently al-
tered growth.
X-ray analysis revealed widespread abnormalities of the skel-
eton in GliLuc mice treated with HhAntag (Figure 3B). In all
treated mice, we found shortened endochondral bones, and
several also displayed grossly abnormal bone structures, partic-
ularly the femur and tibia. Whole skeleton staining with Alizarin
Red S revealed significant joint abnormalities (Figure 3C) similar
to those reported in young mice in which Ihh is conditionally mu-
tated at P0 (Maeda et al., 2007). Histological analysis of longitu-
dinal sections of femurs from 12-week-old mice, previously
treated with HhAntag between P10–P14, revealed malformation
of the epiphysis and growth plate (Figure 3D, upper panels, and
Figures S2A and S2C). The columnar organization of chondro-
cytes in the growth plate was disrupted, and the cartilage struc-
ture appeared dysplastic (Figure 3D, lower panels). The exten-
sive defects in bone growth were not accompanied by any
other major defects in other organs as determined by gross252 Cancer Cell 13, 249–260, March 2008 ª2008 Elsevier Inc.ment were analyzed at 6 weeks of age. We observed an obvious
decrease in the growth of the long bones after only 2–4 days of
treatment (equivalent to four to eight doses of HhAntag,
Figure 4B). More modest effects were observed on bone mor-
phology in mice receiving only two doses of HhAntag over a 24
hr period (Figure 4B). Histological analysis of long bones from
mice receiving six doses of HhAntag indicated malformation of
the epiphysis similar to that observed in mice receiving eight
doses (Figure 3D and 4E). More subtle defects were observed
in the growth plate after four doses of HhAntag (Figure 4D). How-
ever, even with as little as two doses of HhAntag, we detected
aberrations in the femur growth plate (Figure 4E). Extending
the duration of treatment was correlated with progressive short-
ening of the femur, bowing of the fibula, and joint malformation
(Figure 4).
Next, we analyzed the effects of different concentrations of
HhAntag on bone development. Persistent bone defects were
observed in adult mice after exposure to escalating concentra-
tions of HhAntag, given twice daily over a period of 4 days, be-
tween P10 and P14 (Figure S3). No gross malformations were
detected at the lowest concentration tested (10 mg/kg), and
the normal columnar chondrocytic structure was present (Fig-
ures S3B, S3F, and S3J). However, at 25 mg/kg, abnormal
bone formation was observed in the femur epiphysis, and the
Cancer Cell
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(Figure S3C). Instead of the expected zones of maturation, hy-
pertrophy, and calcification, there appears to be a residual
zone of proliferation surrounded by newly synthesized bone.
The femur growth plate seemed more sensitive than that of the
tibia as discontinuities appeared at 25 mg/kg in the femur but
not in the tibia (Figures S3C, S3G, and S3K). The tibia growth
plate was clearly disrupted at a concentration of 100 mg/kg
HhAntag (Figures S3D, S3H, and S3L). Thus, dose escalation
of HhAntag resulted in progressive disruption of bone develop-
ment in young mice.
Figure 3. HhAntag Causes Bone Defects
(A) Changes in body weight during and after 100 mg/kg HhAntag treatment
(pink, Vehicle; yellow and blue, of two wild-type mice and two HhAntag-treated
mice, HhAntag 1 and 2).
(B) Soft X-ray images of 12-week-old mice after eight doses of HhAntag (up-
per, Vehicle; lower, HhAntag).
(C) Skeletal staining of 12-week-old mice treated with Vehicle or with 100 mg/
kg HhAntag between P10 and P14. Insets show magnified knee joints.
(D) H&E staining of longitudinal cross-sections of femurs in 12-week-old mice
after eight doses of Vehicle or HhAntag. Magnified regions show details of the
growth plate. Bars indicate 250 mm (upper panels) and 50 mm (lower panels).HhAntag Blocks Proliferation and Rapidly Promotes
Differentiation of Chondrocytes
Two days of exposure to HhAntag at 100 mg/kg was sufficient to
downregulate whole body GliLuc activity (Figure 5A). Although,
by gross analysis (Alizarin Red S and Alcian blue staining), the
skeleton appeared normal at P12 (Figures S4A–S4E), there
was a dramatic expansion of the hypertrophic zone in the growth
plate (Figure 5B). Safarin O staining revealed disrupted matrix
deposition and premature entry of proliferating chondrocytes
into the terminal hypertrophic state, indicating that the growth
plate had started to withdraw and the columnar organization of
maturing hypertrophic chondrocytes was beginning to break
down (Figures S6B and S6D). There was also a reduction and al-
tered morphology of the perichondrial cell population abutting
the hypertrophic zone (Figures 5C and 5D). After 4 days of treat-
ment, the bone collar was clearly diminished (Figure 5D, arrow-
heads). Ihh is also known to affect perichondrial cells, including
osteoblast progenitors. During embryonic bone development,
Ihh/ embryos display cortical bone defects as well as aberrant
chondrocyte development in the long bones (Colnot et al., 2005;
St-Jacques et al., 1999).
The expansion of the hypertrophic zone was accompanied by
a dramatic decrease in the number of proliferating chondrocytes
in the upper layer of the growth plate, as determined by
5-bromo-2-deoxyuridine (BrdU) labeling (Figure 5E). HhAntag
also appeared to reduce proliferation of osteoblasts (Figures S5E
and S5B). Quantitatively, the number of osteoblasts in the sam-
pled area was reduced by 54.6% ± 16 (n = 6, p = 0.012) after 2
days of treatment and 49.8% ± 20 (n = 6, p = 0.002) after 4
days of treatment.
Withdrawal of HhAntag Promotes Osteogenesis
and Bone Remodeling
The Hh pathway was rapidly restored after cessation of HhAntag
treatment in young mice; however, the defects in bone structure
persisted in adults, indicating that bone remodeling was unable
to repair the structural defects precipitated by HhAntag. Al-
though there was an increase in bone matrix in the growth plate
during the course of treatment, particularly at the chondro-os-
seus junction, this dropped precipitously 2 days after HhAntag
removal (Figure 6A and Figure S6). Two days after cessation of
treatment, the integrity of chondrocyte columnar layers was
lost, and large, irregular spicules containing many osteocytes
appeared in cartilaginous regions (Figure S6F).
Analyses of bone tissue, using markers for several cell popu-
lations including osteoblasts (Col I), prehypertrophic chondro-
cytes (Col II), and hypertrophic chondrocytes (Col X) (Figures
6A–6D), indicated that the chondrocyte population dropped dra-
matically, and the distribution of osteoblasts changed shortly af-
ter HhAntag treatment. It is possible that osteoblasts were re-
cruited to the growth plate following the rapid differentiation
and apoptosis of chondrocytes. Ihh and PTH/PTHrP-R mRNA,
normally present in proliferating, transiting, and prehypertrophic
chondrocytes (Lai and Mitchell, 2005), were also lost from the
growth plate of mice after four doses of HhAntag, whereas the
osteogenic marker genes (MMP13, OPN, and BGP) remained
unchanged (Figure S7). These findings suggest that the majority
of prehypertrophic and hypertrophic chondrocytes differentiated
and died as a result of the transient blockade in Hh activityCancer Cell 13, 249–260, March 2008 ª2008 Elsevier Inc. 253
Cancer Cell
Blocking Hh Pathway Causes Defects in Bone Growthleading to primary spongiosa formation. Microscopic analysis of
H&E-stained sections of the growth plate from P16 mice, com-
pared to those obtained from mice 2 days after treatment with
HhAntag over the P10–P14 period, revealed dramatically en-
hanced bone remodeling (Figures 7A, 7B, 7E, and 7F). It seems
that HhAntag initiated a series of biological processes that re-
sulted in a massive expansion of the region involved in bone re-
modeling. Two days after treatment with HhAntag, the cartilage
plate was drastically reduced, large spicules appeared (Figures
7A, 7B, 7E, and 7F), and osteoclasts and osteoblasts had in-
vaded the growth plate, including the remaining hypertrophic
zone (Figures 7C, 7D, 7G, and 7H). This process was not as
well organized as the orderly synthesis of bone tissue occurring
in normal bone (Figures 7A and 7E). Nevertheless, osteoblasts
and osteoclasts actively remodeled the matrix and triggered tra-
becular bone formation (Figures 7F and 7H), followed by angio-
genesis and incursion of bone marrow. Although the tissue orga-
nization is aberrant, it appears that the same cell types and bone
remodeling processes, observed during normal bone develop-
ment, are responsible for remodeling HhAntag-treated bones.
However, the normal columnar organization normally associated
with this process is lost, so the resulting bone structure is dys-
plastic.
HhAntag Removal Enhances Bone Mineral Deposition
ACF is characterized by the presence of cone-shaped epiphy-
ses, premature fusion of the growth plate, and shortened stature
(Hellemans et al., 2003). Here, we show that HhAntag-treated
mice bear a striking resemblance to ACF. Therefore, we used mi-
cro-CT scanning to determine whether premature fusion of the
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b254 Cancer Cell 13, 249–260, March 2008 ª2008 Elsevier Inc.Figure 4. Severity of Bone Defects Correspond with Period of
HhAntag Treatment
(A and B) Wild-type mice were treated with Vehicle (A) or 100 mg/kg HhAn-
tag (B) twice daily by oral dosing from P10 to P11 (two dose), P10 to P12
(four dose), P10 to P13 (six dose) or P10 to P14 (eight dose). Red arrows
and arrowheads indicate the femurs and knee joints, respectively. Soft
X-ray images were taken when the mice reached 6 weeks of age.
(C and D) Skeletal structure stained with Alizarin Red S in whole mounts
from 6-week-old mice treated with Vehicle (C) and HhAntag (D).
(E) H&E staining of cross sections of the femur in 6-week-old mice after
HhAntag treatment. Scale bars indicate 500 mm.
femur growth plate also occurs in HhAntag-treated mice. Im-
mediately following an eight dose treatment period, there
were no obvious differences in the cartilage structure located
between the epiphysis and diaphysis between control and
treated mice (Figures 6F and 6G, Movies S1 and S2). How-
ever, the cortical bone adjacent to the primary spongiosa
was clearly thinner after HhAntag treatment (Figure 8B).
There was also reduced secondary ossification, in the
spongy structure of existing bone (Figure 8B). In contrast, 2
days after removal of HhAntag, there was a dramatic in-
crease in deposition of minerals in the growth plate and elim-
ination of cartilage between the epiphysis and diaphysis (Fig-
ures 8A and 8B, Movies S3 and S4). Micro-CT data, captured
at the location of endochondral ossification with exclusion of
cortical bone (see Figure S8D), were used to calculate bone
mineral densities (BMD) in treated and untreated mice
Figure 8C). Although no significant changes were observed dur-
ng the course of HhAntag treatment, 2 days after removal of
rug there was a 2-fold increase (p = 0.0057) in BMD in the
rowth plate. This suggests that during HhAntag treatment, ex-
ansion of the hypertrophic zone was not sufficient in itself to
romote mineral deposition; however, removal of HhAntag was
ssociated with a dramatic increase in bone mineralization.
hese findings demonstrate that transient exposure of young
ice to HhAntag causes premature fusion of the growth plate
nd results in permanent defects in bone formation.
ISCUSSION
ransient Hh Pathway Inhibition Causes
ermanent Bone Defects
e developed a vital imaging system for Hh pathway activity
ased on GliLuc transgenic mice. Using these mice, we demon-
trated transient inhibition of Hh pathway activity following oral
elivery of a small molecule antagonist of Smo (HhAntag). Re-
arkably, temporary inhibition of Smo activity in young mice in-
uced a similar phenotype to that caused by conditional muta-
ion of Ihh in postnatal chondrocytes (Maeda et al., 2007). In
oth cases, loss of Hh pathway activity rapidly resulted in differ-
ntiation of chondrocytes, expansion of the hypertrophic zone,
nd a breakdown in columnar organization. Restoration of
mo activity after drug removal precipitated bone mineralization
nd premature fusion of the growth plate. Although chondrocyte
roliferation recovered, the population was significantly re-
uced. Disruption of growth plate structure led to shortened
ones and aberrations of the articular surfaces that resulted in
Cancer Cell
Blocking Hh Pathway Causes Defects in Bone Growthpermanent defects in joint structures. These findings demon-
strate that continuous Smo activity is required to maintain post-
natal bone structures and that even transient loss of Hh signaling
Figure 5. HhAntag Promotes Differentiation and Inhibits Prolifera-
tion of Chondrocytes
(A) Photograph, bioluminescence images, and quantitation of Hh pathway ac-
tivity in P12 GliLuc transgenic mice after 2 days of treatment with Vehicle or
100 mg/kg HhAntag. Data indicate mean ± SD (n = 3).
(B) H&E staining of longitudinal cross-sections from the femurs of treated mice.
Vertical lines indicate the extent of the prehypertrophic and hypertrophic chon-
drocytic layers. Graph illustrates the relative length of these layers measured
from cross-sections (n = 6). Data indicate mean ± SD. Scale bars indicate
250 mm.
(C) Magnified view of the area indicated by black boxes in (B) showing the peri-
chondrium at P12. Scale bar indicates 50 mm.
(D) View of the perichondium and surrounding tissue at P14 (magnified from
Figure S5A). A dotted lineoutlines theperichondrium. Scalebar indicates 50mm.
(E) BrdU labeling and immunostaining of longitudinal cross-sections from P14
femurs from Vehicle- and HhAntag-treated mice. The black box encloses chon-
drocytes in the proliferative zone. The region surrounded by a dotted line is
primary spongiosa. The number of BrdU-positive cells in sections was counted
(n = 6).
Values shown in graphs are mean ± SD. V, Vehicle; H, HhAntag. Scale bars in-
dicate 250 mm. Asterisk indicates statistical significance by Student’s t test with
p < 0.01.can result in long-term defects. Bone remodeling was not suffi-
cient to overcome the structural alterations triggered by as little
as 2 days of inhibition of Hh pathway activity in young mice. This
result shows that short-term exposure to signal transduction in-
hibitors during development can have long-term consequences.
Therefore, our findings raise concerns about the potential side
effects associated with cancer therapies targeting the Hh path-
way in children.
HhAntag Affects Developing Bone
During development, endochondral ossification relies on the
maintenance of a strict zonal organization in the epiphyseal
growth plate. The pathogenesis associated with HhAntag treat-
ment is the consequence of a breakdown of this elegant struc-
ture. After a few days of HhAntag treatment, there is depletion
of the proliferative zone, expansion of the zone of hypertrophy,
and disruption of the columnar organization that underlies endo-
chondral ossification. Removal of the drug reactivates the Hh
pathway and promotes calcification and aberrant synthesis of
trabecular bone. The formation of inappropriate bony trabeculae
creates permanent structural alterations that cannot be removed
by bone remodeling. Reduced proliferation and increased differ-
entiation of condrocytes leads to shortening of the bones and
dwarfism. These findings demonstrate the continuous need for
Hh signaling in maintaining postnatal bone structures. Perma-
nent deletion of Ihh in chondrocytes of mice carrying conditional
and inducible null alleles of Ihh results in a similar phenotype to
that reported here (Maeda et al., 2007; Razzaque et al., 2005),
so clearly the pathway has an ongoing role in bone development.
However, the remarkable finding reported here is that even tem-
porary inhibition of Smo activity for as little as 48 hr is sufficient to
disrupt bone development in young mice.
Previously, we treated adult mice for prolonged periods with
HhAntag and observed no weight loss. In GliLuc mice, although
the overall luciferase signal was much reduced in adults, there
was a low but detectable signal level in skin (Figure 1D). How-
ever, this signal could not be inhibited by treatment with HhAntag
(Figure S9), and therefore, it might be a consequence of basal Gli
transcriptional activity that is not regulated by Smo. Several adult
stem cell populations utilize Hh signaling (Ahn and Joyner, 2005;
Mimeault and Batra, 2006), and they have the potential to be ad-
versely affected by transient inhibition of the pathway. However,
we have not observed any other deleterious effects of HhAntag
treatment of adult mice, with the exception of a temporary inhi-
bition of the continuous growth of incisor teeth (J. Romer and
T.C., unpublished data), which is characteristic of adult mice
but does not occur in humans. Thus, the effects observed here
in young mice appear to be specific for developing bone and
would not be expected to occur in healthy adults.
Inhibition of Bone Growth Requires Less HhAntag
Than Antitumor Effects
Elimination of MB in Ptc1+/p53/ mice requires 100 mg/kg
HhAntag delivered orally twice a day for a period of 2 weeks (Ro-
mer et al., 2004; Sasai et al., 2006). At 20 mg/kg, there was still
substantial residual tumor volume at the end of the 2 week period
of treatment (Romer et al., 2004). When the drug was given for
a shorter treatment period (4 days), there was little reduction in
tumor volume, although there was a clear histological responseCancer Cell 13, 249–260, March 2008 ª2008 Elsevier Inc. 255
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dicated that a prolonged period of exposure to high drug con-
centrations is required to eliminate tumor mass.
Pharmacokinetic studies indicated that HhAntag is rapidly
cleared from the system so the levels of drug drop below the
therapeutic threshold unless the dose is high (Romer et al.,
2004). In contrast, the on-target side effect reported here re-
quires only brief exposure to inhibitory concentrations of drug.
Figure 6. HhAntag Alters the Osteoblast and Chondrocyte Pop-
ulations in the Growth Plate
(A–E) Safranin O staining (A) and in situ hybridization analysis (B–E) of bone
markers in the femur growth plate of mice during and after treatment with
100 mg/kg HhAntag. P12 mice were analyzed after treatment for 2 days
(four-dose treatment) or P16 mice after 4 days of treatment (eight dose)
followed by a 2 day rest period. The probes used were Col I (B), Col II
(C), Col X (D), and Smo (control, [E]). Images of RNA expression were vi-
sualized as red pseudocolor. PC, proliferative chondrocyte zone; HC, hy-
pertrophic chondrocyte zone; TB, trabecular bone. Scale bars indicate
250 mm. Asterisk indicates statistically significant with Student’s t test
(p < 0.01).
We found that even as little as 10 mg/kg HhAntag substan-
tially suppressed Hh pathway activity in skin after 2 days of
treatment, and the effect was maximal at 25 mg/kg. Four
days of treatment with 25 mg/kg HhAntag resulted in clear
histological defects in bone structure. Suppressing the path-
way with 100 mg/kg given twice daily caused permanent de-
fects in bone structure after only 2 days of exposure. Thus,
chondrocyte progenitor cells are highly susceptible to the ef-
fects of HhAntag. Previously, we found that HhAntag rapidly
inhibits tumor cell proliferation but only modestly increases
the rate of cell death. Therefore, the pathway may need to
be completely suppressed in tumor cells for a prolonged pe-
riod for tumor elimination. In contrast, even brief exposure of
proliferating chondrocytes to HhAntag results in terminal dif-
ferentiation. In an attempt to define a therapeutic window for
HhAntag use in young mice, we treated five Ptc1+/p53/
mice with 5 mg/kg HhAntag orally twice daily for 2 weeks starting
on P10. Four of these mice developed medulloblastoma within
61 days (all controls developed medulloblastoma within 58
days), and one mouse survived to day 81, when the experiment
was terminated. None of the treated mice showed any evidence
of bone defects (Figure S10). These findings imply that it will not
be possible to find a level of HhAntag that inhibits tumor growth in
young mice without also causing defects in bone development.Figure 7. Osteoclasts Invade in the Expanded Primary Spon-
giosa Region after HhAntag Removal
(A, B, E, and F) H&E staining and (C, D, G, and H) TRAP staining in the
growth plate of P16 mice after 4 days of treatment with (B, F, D, and H)
or without (A, E, C, and G) 100 mg/kg HhAntag followed by a 2 day rest
period. Arrowheads indicate TRAP-positive osteoclasts. Scale bars indi-
cate 100 mm and 25 mm (E–H).256 Cancer Cell 13, 249–260, March 2008 ª2008 Elsevier Inc.
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Several studies have suggested that the Hh pathway is a suitable
target for therapeutic intervention in many cancers, not just
those such as BCC and MB, that harbor Ptc1 mutations (Berman
et al., 2003; Karhadkar et al., 2004; Sanchez et al., 2004; Watkins
et al., 2003). In some cases, it has been suggested that upregu-
lation of Hh ligands in tumors or stromal cells drives tumor cell
proliferation, but in others the Hh pathway is thought to be impor-
tant for maintenance of stromal cells and the cancer stem cell
niche (Rubin and de Sauvage, 2006). Thus, the potential thera-
peutic indication of Hh pathway antagonists is quite broad.
One note of caution, however, is that many of these studies em-
ployed cyclopamine in preclinical models to reach these conclu-
sions. We found that the Hh pathway is rapidly downregulated in
Figure 8. HhAntag Causes Premature Fusion of the Growth Plate
and Increased Bone Mineral Density
(A and B) Micro-CT analyses of femurs from 14-day-old mice after 2 days of
treatment (four dose) and 16-day-old mice after 4 days of treatment (eight
dose) followed by a 2 day rest period. Scale bars indicate 500 mm. (A) Three-
dimensional structural rendering of the femur. (B) Longitudinal cross-section
CT images of the femur. EP, epiphysis; DI, diaphysis; SO, secondary ossifica-
tion; C, cartilage; TB, trabecular bone. Red bracket and arrow indicate epiph-
ysis and cortical bone abutting the perichondrium, respectively.
(C) Bone mineral density of trabecular bones in 20 slices from the front of en-
dochondral ossification. V, Vehicle; H, HhAntag. Values shown at graphs are
mean ± SD (eight-dose treatment, n = 4; 2 days posttreatment, n = 3). Asterisk
indicates statistically significant by Student’s t test with p < 0.01.cultured medulloblastoma cells, and it does not recover when
these cells are propagated in allografts (Sasai et al., 2006).
Therefore, one should be cautious in interpreting the results of
drug studies concerning inhibition of the Hh pathway based
only on cell lines or tumors derived from cell lines. Furthermore,
functional imaging of the Hh pathway in GliLuc mice allowed us
to compare the efficacy of cyclopamine to that of HhAntag. We
found that cyclopamine was less efficient at suppressing Hh
pathway activity both in vitro and in vivo (Romer et al., 2004)
(Figure S1). In addition, cyclopamine caused several serious
side effects in young mice, including weight loss and dehydra-
tion, so we were not able to achieve a therapeutic dose in this
model system. There are several possible explanations for the
discrepancies with published studies. Each mouse strain may
have differential sensitivity to cyclopamine, and it is also possible
that young mice are more affected by the toxic side effects. In
our experiments, we delivered cyclopamine by oral gavage,
whereas other studies injected the compound so there may be
differences in bioavailability using these different approaches.
Nevertheless, it is difficult to interpret the effects of cyclopamine
in vitro and in mouse models because of these issues.
Implications for Treatment of Human MB
Pediatric MB is the most common malignant primary central ner-
vous system tumor of childhood with peak incidence at 7 years
of age. Current therapy, involving a combination of surgery, radi-
ation, and chemotherapy, is relatively successful with a 5 year
survival rate of 78%. However, the prognosis is much worse
for patients younger than 3 and in older patients with metastatic
disease (Gilbertson, 2004). There is also significant morbidity as-
sociated with treatment, including endocrine and neuropsycho-
logical deficits, particularly in younger patients. Thus, there is
a great need for alternative therapies.
At present, it is not clear that the developmental bone toxicities
observed in mice would also occur in humans. Mice undergo ex-
tremely rapid bone growth during the period of treatment from
P10 to P14. The period of most rapid bone growth in humans
is just prior to the onset of puberty. It is possible that the exact
age and duration of therapy could be chosen to minimize the im-
pact on bone development. At present, it is difficult to gauge the
extent of side effects that could be encountered in children to de-
termine the cost versus the benefit of this therapeutic approach.
Previously, we did not observe any major side effects after
HhAntag treatment of adult mice (Romer et al., 2004). However,
we must consider the possibility that transient inhibition of Hh
pathway activity could result in compromised regenerative ca-
pacity in some adult tissues. These deficits may not be apparent
until exposure of treated individuals to some form of physiolog-
ical stress (e.g., surgery). Intramembranous ossification, al-
though different from endochondral bone development, is af-
fected by mutation of Ihh, and it is at least conceivable that
cranium healing after surgery could be compromised.
To limit the potential side effects of Hh pathway inhibitors in
pediatric brain tumor patients it is possible that drug targeting
strategies may be adopted to limit the distribution of compounds
to the craniospinal axis. In addition, while all of the blockers de-
scribed to date appear to bind to the same target site on Smo,
different chemical classes may distribute differentially, and it
might be possible to identify compounds that selectively targetCancer Cell 13, 249–260, March 2008 ª2008 Elsevier Inc. 257
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bone tissue during the period of treatment. Thus, although the
impact of a brief suppression of Hh pathway on bone develop-
ment in mice is quite striking, this should not preclude attempts
to develop a highly promising anticancer treatment for pediatric
MB. MB also occurs, albeit at a lower incidence, in adults and in
older children who have completed the majority of their growth.
These patients, as well as adult or pediatric patients with recur-
rent disease, may well benefit from treatment with compounds
specific for the Hh pathway. Hh pathway inhibitors could also
be used at low doses in patients with germline mutations of
PTCH1 as cancer prevention agents or to reduce the other phe-
notypic consequences of increased pathway activity.
EXPERIMENTAL PROCEDURES
Generation of GliLuc Transgenic Mice
Six transgenic founder mice were identified following pronuclear injection of
a transgene containing eight Gli binding sites fused to the luciferase gene (Gli-
Luc) (Sasaki et al., 1997) into fertilized FVB/NJ oocytes. Mouse lines were
propagated by crossing with FVB/NJ wild-type mice. Luciferase activity was
confirmed using mouse embryonic fibroblasts (MEFs) and cerebellar granule
cell cultures derived from GliLuc transgenic mice. Cells from only one line ex-
hibited a robust increase in luciferase activity following treatment with Hh (data
not shown). Reporter-positive mice were identified by PCR using primers to
the promoter region 50- CCGGGAACAGATTCGCGATCGACC-30 and the lucif-
erase gene 50- CAGTTGCTCTCCAGCGGTTCCATC-30.
Mice were housed in an American Association of Laboratory Animal Care-
accredited facility and maintained in accordance with NIH Guidelines for the
Care and Use of Laboratory Animals. The Institutional Animal Care and Use
Committee at St. Jude Children’s Research Hospital approved all procedures
for animal use.
Bioluminescence Imaging and Luciferase Assays
Mice were anesthetized with intranasal isoflurane, and imaging was initiated
5 hr after the last drug treatment. D-Luciferin (150 mg/kg) in PBS was injected
intraperitoneally prior to imaging. Bioluminescence imaging with a CCD cam-
era (IVIS200, Xenogen) was carried out 5 min after injection of D-Luciferin. A 10
s bioluminescent image was captured in a 19.5 cm field of view, using a binning
factor of 8, 1 f/stop, and an open filter. Signal intensities from regions of inter-
est were defined manually, and data were expressed as total photon flux (pho-
ton per sec per area). Images (n = 3) were taken when luciferase signals
reached steady state by IVIS200 (Xenogen) monitoring.
MEFs were prepared from E13.5 GliLuc mice and cultured in DMEM with
10% fetal bovine serum according to standard procedures. Tertiary fibroblasts
were plated and cultured for 2 days until confluent at which point either Shh
alone or Shh plus HhAntag were added to culture media. Two days later, lumi-
nescence images were taken following addition of D-Luciferin (1.5 mg/ml). Al-
ternatively, cells were harvested, and cell extracts were prepared for lumines-
cence assays according to manufacturer’s specifications (Promega). Assays
were performed in triplicate.
In Situ Hybridization
For bone tissues, paraffin sections were dewaxed, hydrated, and treated with
proteinase K (20 mg/ml). Sections were treated with triethanolamine/acetic an-
hydride and dehydrated. Prehybridization and hybridization were performed at
50C for 1 hr and overnight, respectively, using 35S-UTP labeled riboprobes for
Col I, Col II, Col X, and Smo. Slides were washed in 50% formamide/23 SSC
and treated with RNase A. After dehydration, slides were dipped in emulsion
and exposed for 1–4 weeks. Slides were counterstained with Hoechst
33258. Images were captured using NIS-Elements software (Nikon).
Chemicals
HhAntagonist (HhAntag) was obtained from Genentech, Inc. (South San Fran-
cisco, CA). HhAntag is available from Genentech under a material transfer
agreement, available at http://www.gene.com/gene/about/collaborations/
258 Cancer Cell 13, 249–260, March 2008 ª2008 Elsevier Inc.contracts.jsp. HhAntag details are included in US patent WO 2003011219,
available from the web site http://l2.espacenet.com/espacenet/
viewer?PN=WO03011219. HhAntag was prepared in DMSO for tissue culture
and in 0.5% Methylcellulose/0.2% Tween 80 for oral dosing. Cyclopamine
(Toronto Research Chemicals) was suspended in 10% EtOH/90% Labrafil
(GATTEFOSSE) for oral dosing.
Soft X-Ray and Skeletal Staining
Bone X-ray images were taken under anesthesia by Specimen Radiography
System (Faxitron X-Ray Corp). Skeletons were prepared according to a modi-
fied protocol based on that of McLeod (McLeod, 1980). Adult mice were sac-
rificed, skinned, eviscerated in PBS, and fixed in 95% EtOH. Subsequently,
acetone was used to remove fat. Then, skeletons were stained with 0.015%
Alcian Blue and 0.005% Alizarin Red. Samples were cleared in 2% KOH over-
night before transferring sequentially through 20% glycerol solution in 1%
KOH for 7 days, 20% glycerol in 20% EtOH, and 50% glycerol in 50% EtOH
overnight, respectively. Skeletons were stored in 100% glycerol.
Histopathology of Bone Tissues
Mice were injected with BrdU (100 mg/kg) in PBS 1 hr before perfusion with 4%
paraformaldehyde (PFA) in PBS at 5 hr after the last Vehicle or HhAntag treat-
ment. Bone samples were postfixed in 10% buffered formalin or 4% PFA and
decalcified in 14% EDTA for 2 weeks or Morse’s solution for 1 to 2 days at 4C
(Shibata et al., 2000). Bone tissues were embedded in paraffin. Thin sections
(5 mm) were stained with hematoxylin and eosin (H&E) according to standard
protocols. BrdU immunostaining was carried out according to the manufac-
turer’s protocol (Zymed). Safranin O staining was performed in Wegret’s iron
hematoxylin working solution (Sigma), 0.001% fast green (FCF), and 0.1% Saf-
ranin O solutions (Sigma). The TRAP method for identifying osteoclasts was
performed according to manufacturer’s instructions (Sigma).
Micro-CT
After cardiac perfusion with 4% PFA, rear legs were dissected and fixed in 4%
PFA at 4C for 2 days, rinsed with PBS, and placed in 70% EtOH at 4C. Fe-
murs were scanned using GE explore Locus SP Pre-Clinical Specimen mi-
cro-CT operated at 16 mm isotropic voxel resolution. Bone tissues were com-
puted with GE Healthcare MicroView software for visualization and analysis of
volumetric image data.
SUPPLEMENTAL DATA
The Supplemental Data include ten supplemental figures and four supplemen-
tal movies and can be found with this article online at http://www.cancercell.
org/cgi/content/full/13/3/249/DC1/.
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